Seres Therapeutics’ SER-155 Shows Promising Clinical Results

Seres Therapeutics, Inc. shared promising results from their SER-155 Phase 1b study, indicating that the treatment led to a significant decrease in bloodstream infections and systemic antibiotic use in patients undergoing stem cell transplantation.